Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of the North American Menopause Society

Menopause

Volumn 11, Issue 6 I, 2004, Pages 589-600

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

CLIMACTERIUM; DEMENTIA; DRUG CHOICE; DRUG INDICATION; DRUG SAFETY; DRUG USE; ESTROGEN THERAPY; FEMALE; HUMAN; LOW DRUG DOSE; MEDICAL DECISION MAKING; MEDICAL EXPERT; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRESCRIPTION; REVIEW; RISK BENEFIT ANALYSIS; STROKE; TREATMENT INDICATION;

ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; PROGESTINS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 14844352009     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000145876.76178.dc     Document Type: Review

References (113)

1. The North American Menopause Society. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause 2003;10:6-12. Level of evidence: III.
2. The North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: September 2003 position statement of The North American Menopause Society. Menopause 2003;10: 497-506. Level of evidence: III.
3. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002;287: 591-597. Level of evidence: I.
4. Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100:1209-1218. Level of evidence: I.
5. Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 2004;103:254-260. Level of evidence: II-2.
6. Anderson GL, Limacher M, Assaf AR, et al, for the Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 2004;291:1701-1712. Level of evidence: I.
7. Hays J, Ockene JK., Brunner RL, et al, for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-1854. Level of evidence: I.
8. Gordon S, Walsh BW, Ciaccia AV, Siddhanti S, Rosen AS, Plouffe L. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms. Obstet Gynecol 2004;103:267-273. Level of evidence: I.
9. Salpeter SR, Walsh JME, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791-804. Level of evidence: III. Meta-analysis.
10. Utian WH, Janata JW, Kingsberg SA, Schluchter M, Hamilton JC. The Utian Quality of Life (UQOL) Scale: development and validation of an instrument to quantify quality of life through and beyond menopause. Menopause 2002;9:402-410. Level of evidence: II-3.
11. Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause 2004;11:120-130. Level of evidence: review.
12. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes (Cochrane Review). Cochrane Database Syst Rev 2001;1:CD002978. Level of evidence: III.
13. Soares CN, Poitras JR, Prouty J. Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause. Drugs Aging 2003;20:85-100. Level of evidence: Review.
14. Brett KM, Reuben CA. Prevalence of estrogen or estrogen-progestin hormone therapy use. Obstet Gynecol 2003;102:1240-1249. Level of evidence: II-3.
15. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-1232. Level of evidence: Telephone survey.
16. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and responses to recent evidence. JAMA 2004;291:47-53. Level of evidence: Database review.
17. Women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-1087. Level of evidence: I.
18. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287:2668-2676. Level of evidence: I.
19. Pickar JH, Yeh I-T, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003;80:1234-1240. Level of evidence: I.
20. Utian WH, Gass MLS, Pickar JH. Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in younger, postmenopausal women. Menopause 2004;11:306-314. Level of evidence: I.
21. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079. Level of evidence: I.
22. Brynhildsen J, Hammar M. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. Menopause 2002;9:137-144. Level of evidence: I.
23. Hashimoto M, Miyao M, Akishita M, et al. Effects of long-term and reduced-dose hormone replacement therapy on endothelial function and intima-media thickness in postmenopausal women. Menopause 2002;9: 58-64. Level of evidence: II-1.
24. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17β-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003;290:1042-1048. Level of evidence: I.
25. Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 1996;88:587-592. Level of evidence: I.
26. Utian WH, Burry KA, Archer DF, et al. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients: the Esclim Study Group. Am J Obstet Gynecol 1999;181:71-79. Level of evidence: I.
27. The North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003;10:113-132. Level of evidence: III.
28. Warren MP. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gyncol 2004;190: 1141-1157. Level of evidence: Review.
29. Scarabin P-Y, Oger E, Plu-Bureau G, for the EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432. Level of evidence: II-2.
30. Hodis HN, Mack WJ, Lobo RA, et al, for Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-953. Level of evidence: I.
31. Cherry N, Gilmour K, Hannaford P, et al, for The ESPRIT team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002;360:2001-2008. Level of evidence: I.
32. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529. Level of evidence: I.
33. Mack WJ, Hameed AB, Xiang M, et al. Does elevated body mass modify the influence of postmenopausal estrogen replacement on atherosclerosis progression: results from the estrogen in the prevention of atherosclerosis trial. Atherosclerosis 2003;168:91-98. Level of evidence: I.
34. Herrington DM, Vittinghoff E, Lin F, et al, for the HERS Study Group. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002;105:2962-2967. Level of evidence: I.
35. Hsia J, Simon JA, Lin F, et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. Circulation 2000;102:2228-2232. Level of evidence: I.
36. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638-642. Level of evidence: I.
37. Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57. Level of evidence: II-2.
38. Hulley S, Furberg C, Barrett-Connor E, et al, for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66. Level of evidence: II-2.
39. Vittinghoff E, Shlipak MG, Varosy PD, et al, for the Heart and Estrogen/progestin Replacement Study research group. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2003;138:81-89. Level of evidence: II-2.
40. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941. Level of evidence: II-2.
41. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-461. Level of evidence: II-2.
42. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol 2002;109:1056-1062. Level of evidence: I.
43. Barrett-Connor E, Slone S, Greendale G, et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas 1997;27:261-274. Level of evidence: I.
44. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial [erratum in: JAMA 1995;214:1616]. JAMA 1995;273:199-208. Level of evidence: I.
45. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial [erratum in: JAMA 1995;214:1616]. JAMA 1995;273:199-208. Level of evidence: I.
46. Scarabin PY, Oger E, Plu-Bureau G, for the Estrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432. Level of evidence: II-2.
47. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-2440. Level of evidence: I.
48. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-49. Level of evidence: I.
49. Hodis HN, Mack WJ, Azen SP, et al, for the Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349: 535-545. Level of evidence: I.
50. Manson JE, Hsia J, Johnson KC, et al, for the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534. Level of evidence: I.
51. Margolis KL, Bonds DE, Rodabough RJ, et al, for the Women's Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175-1187. Level of evidence: I.
52. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al, for the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-2684. Level of evidence: I.
53. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. Level of evidence: I.
54. Bairey Merz CN, Johnson BD, Sharaf BL, et al, for the WISE Study Group. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLB1-sponsored WISE Study. J Am Coll Cardiol 2003;41:413-419. Level of evidence: II-2.
55. Hu FB, Grodstein F, Hannekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999;159:1061-1066. Level of evidence: II-2.
56. Angerer P, Kothny W, Störk S, von Schacky C. Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial. J Am Coll Cardiol 2000;36:1786-1796. Level of evidence: I.
57. Angerer P, Störk S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-268. Level of evidence: I.
58. Chilvers CE, Knibb RC, Armstrong SJ, Woods KL, Logan RF. Post menopausal hormone replacement therapy and risk of acute myocardial infarction: a case control study of women in the East Midlands, UK. Euro Heart J 2003;24:2191-2205. Level of evidence: II-2.
59. Ferrara A, Quesenberry CP, Karter AJ, Njoroge CW, Jacobson AS, Selby JV, for the Northern California Kaiser Permanente Diabetes Registry. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation 2003;107:43-48. Level of evidence: II-3.
60. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy early postmenopausal women. Arch Intern Med 2004; 164:482-484. Level of evidence: I.
61. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-284. Level of evidence: Review.
62. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1998; 158:585-593. Level of evidence: Database review.
63. Hulley S, Furberg C, Barrett-Connor E, et al, for the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66. Level of evidence: I.
64. Banks E, Beral V, Reeves G, Balkwill A, Barnes I, for the Million Women Study Collaborators. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 2004;291: 2212-2220. Level of evidence: II-2.
65. Barrett-Connor E, Wehren LE, Siris ES, et al. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause 2003;10:412-419. Level of evidence: II-2.
66. Yates J, Barrett-Connor E, Barlas S, Chen YT, Miller PD, Siris ES. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004; 103:440-446. Level of evidence: II-2.
67. Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E, for the PEPI Safety Follow-up Study (PSFS) Investigators. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) safety follow-up study. Arch Intern Med 2002;162:665-672. Level of evidence: I.
68. Greendale GA, Wells B, Marcus R, Barrett-Connor E, for the Postmenopausal Estrogen/Progestin Interventions trial investigators. How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions trial. Arch Intern Med 2000;160:3065-3071. Level of evidence: I.
69. The Writing Group for the PEPI trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996;276:1389-1396. Level of evidence: I.
70. Bagger YZ, Tanko LB, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-735. Level of evidence: II-2.
71. Cauley JA, Robbins J, Chen Z, et al, for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-1738. Level of evidence: I.
72. Gallagher JC, Rapuri PB, Haynatzki G, Detter JR. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 2002;87:4914-4923. Level of evidence: I.
73. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:875-883. Level of evidence: I.
74. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359:2018-2026. Level of evidence: Review.
75. The North American Menopause Society. Management of postmenopausal osteoporosis: position statement of The North American Menopause Society. Menopause 2002;9:84-101. Level of evidence: III.
76. Wells G, Tugwell P, Shea B, et al, for the Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-539. Level of evidence: III.
77. Zandi PP, Carlson MC, Plassman BL, et al, for the Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002;288:2123-2129. Level of evidence: II-3.
78. Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med 2002;113: 543-548. Level of evidence: I.
79. Henderson VW, Guthrie JR, Dudley EC, Burger HG, Dennerstein L. Estrogen exposures and memory at midlife: a population-based study of women. Neurology 2003;60:1369-1371. Level of evidence: II-2.
80. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg and Psychiatry 2004 [in press]. Level of evidence: II-2.
81. Meyer PM, Powell LH, Wilson RS, et al. A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology 2003;61:801-806. Level of evidence: II-2.
82. Espeland MA, Rapp SR, Shumaker SA, et al, for the Women's Health Initiative Memory Study Investigators. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2959-2968. Level of evidence: I.
83. Rapp SR, Espeland MA, Shumaker SA, et al, for the WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2663-2672. Level of evidence: I.
84. Shumaker SA, Legault C, Kuller L, et al, for the Women's Health Initiative Memory Study Investigators. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-2958. Levels of evidence: I.
85. Shumaker SA, Legault C, Thai L, et al, for the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289: 2651-2662. Level of evidence: I.
86. den Heijer T, Geerlings MI, Hofman A, et al. Higher estrogen levels are not associated with larger hippocampi and better memory performance. Arch Neurol 2003;60:213-220. Level of evidence: II-2.
87. Morrison MF, Kallan MJ, Ten Have T, Katz I, Tweedy K, Battistini M. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry 2004;55:406-412. Level of evidence: I.
88. Thai LJ, Thomas RG, Mulnard R, Sano M, Grundman M, Schneider L. Estrogen levels do not correlate with improvement in cognition. Arch Neurol 2003;60:209-212. Level of evidence: II-2.
89. Henderson VW. Hormone therapy and Alzheimer's disease: benefit or harm? Expert Opin Pharmacother 2004;5:389-406. Level of evidence: Review.
90. Holmberg L, Anderson H, for the HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomized comparison trial stopped. Lancet 2004;363:453-455. Level of evidence: I (no placebo).
91. Beral V, for the Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427. Level of evidence: II-2.
92. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-269. Level of evidence: I.
93. Anderson GL, Judd HL, Kaunitz AM, et al, for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-1748. Level of evidence: I.
94. Chlebowski RT, Hendrix SL, Langer RD, et al, for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-3253. Level of evidence: I.
95. McTiernan A, Kooperberg C, White E, Wilcox S, Coates R, Adams-Campbell LL, Woods N, Ockene J. Women's Health Initiative Cohort Study. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA. 2003;290:1331-1336. Level of evidence: II-2.
96. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. Level of evidence: I.
97. Lacey JV Jr, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer [erratum in: JAMA 2002;288: 2544]. JAMA 2002;288;334-341. Level of evidence: II-2.
98. Lacey JV Jr, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer [erratum in: JAMA 2002;288: 2544]. JAMA 2002;288;334-341. Level of evidence: II-2.
99. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-3263. Level of evidence: II-2.
100. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;97:1387-1392. Level of evidence: II-2.
101. Weiss LK, Burkman RT, Cushing-Hauger KL, et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002;100:1148-1158. Level of evidence: II-2.
102. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer [erratum in: Lancet 1997;350: 1484]. Lancet 1997;350:1047-1059. Level of evidence: III.
103. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer [erratum in: Lancet 1997;350: 1484]. Lancet 1997;350:1047-1059. Level of evidence: III.
104. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616. Level of evidence: III.
105. Montgomery BE, Daum GS, Dunton CJ. 2004. Endometrial hyperplasia: a review. Obstet Gynecol Survey 59:368-78. Level of evidence: Review.
106. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al, for the Women's Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;250: 991-1004. Level of evidence: I.
107. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574-582. Level of evidence: III.
108. MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies. Med J Aust 1995;162:491-493. Level of evidence: III.
109. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999;93:880-888. Level of evidence: III.
110. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-650. Level of evidence: III.
111. Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: A review. Menopause 2004;11:356-367. Level of evidence: Review.
112. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998;280: 1930-1935. Level of evidence: III.
113. Council for International Organizations of Medical Sciences (CIOMS). Guidelines for Preparing Core Clinical-Safety Information of Drugs, 2nd ed. Geneva, Switzerland: CIOMS; 1998, Level of evidence: review.